Novo Nordisk filed patent litigation against telehealth firm Hims & Hers over an allegedly infringing semaglutide pill and is seeking substantial damages. The complaint centers on Hims’ pill formulation and mass‑marketing of a product Novo says lacks the SNAC absorption technology used in the approved Wegovy tablet. FDA commissioner Marty Makary publicly warned regulators will act swiftly against companies mass‑marketing unapproved copycat drugs, amplifying regulatory and legal pressure on compounding and telehealth competitors. Markets reacted quickly; Novo’s shares rose on the enforcement signal. The dispute raises immediate questions about quality, delivery technologies, and the retailized rollout of obesity medicines.